Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

First Posted Date
2022-01-12
Last Posted Date
2024-11-06
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
20
Registration Number
NCT05188118
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Renal Cell Carcinoma
Interventions
Drug: Anlotinib hydrochloride
Drug: everolimus
First Posted Date
2021-11-18
Last Posted Date
2021-11-18
Lead Sponsor
Fudan University
Target Recruit Count
30
Registration Number
NCT05124431
Locations
🇨🇳

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

First Posted Date
2021-11-05
Last Posted Date
2021-12-09
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT05108740

Lenvatinib with Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

First Posted Date
2021-08-19
Last Posted Date
2024-10-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
90
Registration Number
NCT05012371
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

First Posted Date
2021-06-09
Last Posted Date
2024-08-12
Lead Sponsor
ITM Solucin GmbH
Target Recruit Count
250
Registration Number
NCT04919226
Locations
🇮🇳

Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging, Mumbai, India

🇫🇷

Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, Cedex, France

🇺🇸

University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 40 locations

Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients

Phase 4
Conditions
Liver Transplant
Interventions
Drug: Everolimus
First Posted Date
2021-04-30
Last Posted Date
2021-04-30
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
112
Registration Number
NCT04867720
Locations
🇰🇷

Seoul National University Hosipital, Seoul, Korea, Republic of

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

First Posted Date
2021-04-19
Last Posted Date
2021-04-19
Lead Sponsor
University of Cincinnati
Target Recruit Count
120
Registration Number
NCT04849533
Locations
🇺🇸

The Christ Hospital, Cincinnati, Ohio, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

First Posted Date
2021-03-17
Last Posted Date
2024-12-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
510
Registration Number
NCT04802759
Locations
🇺🇸

Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States

🇺🇸

Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States

🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

and more 25 locations

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

First Posted Date
2020-12-14
Last Posted Date
2024-11-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
108
Registration Number
NCT04665739
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Tower Cancer Research Foundation, Beverly Hills, California, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy